You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Overview

  • Product nameAnti-Cyclin D1 antibody [CD1.1]See all Cyclin D1 primary antibodies ...
  • Description
    Mouse monoclonal [CD1.1] to Cyclin D1
  • SpecificityRecognises Cyclin D1
  • Tested applicationsIHC-P, IHC-Fr, Flow Cyt, WB, IP, ELISA, ICC more details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Full length protein (Human).

  • Positive controlSmall intestine, colon

Properties

Applications

Our Abpromise guarantee covers the use of ab6152 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
IHC-P IHC-P: 1/1000 - 1/10000. We recommend antigen retrieval with sodium citrate buffer pH 6 before IHC staining.
IHC-Fr IHC-Fr: Use at an assay dependent dilution.
Flow Cyt Flow Cyt: Use at an assay dependent dilution.
WB WB: 1/500. Predicted molecular weight: 33 kDa.
IP IP: Use at an assay dependent dilution.
ELISA ELISA: Use at an assay dependent dilution.
ICC ICC: Use a concentration of 1 µg/ml.

Target

  • FunctionEssential for the control of the cell cycle at the G1/S (start) transition.
  • Involvement in diseaseNote=A chromosomal aberration involving CCND1 may be a cause of B-lymphocytic malignancy, particularly mantle-cell lymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulin gene regions. Activation of CCND1 may be oncogenic by directly altering progression through the cell cycle.
    Note=A chromosomal aberration involving CCND1 may be a cause of parathyroid adenomas. Translocation t(11;11)(q13;p15) with the parathyroid hormone (PTH) enhancer.
    Defects in CCND1 are a cause of multiple myeloma (MM) [MIM:254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving CCND1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus.
  • Sequence similaritiesBelongs to the cyclin family. Cyclin D subfamily.
  • Post-translational
    modifications
    Phosphorylation at Thr-286 by MAP kinases is required for ubiquitination and degradation following DNA damage. It probably plays an essential role for recognition by the FBXO31 component of SCF (SKP1-cullin-F-box) protein ligase complex.
    Ubiquitinated, primarily as 'Lys-48'-linked polyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-box protein) ubiquitin-protein ligase complex containing FBXO4 and CRYAB (By similarity). Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. Ubiquitination leads to its degradation and G1 arrest. Deubiquitinated by USP2; leading to stabilize it.
  • Cellular localizationNucleus.
  • Target information above from: UniProt accession P24385 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
  • Alternative names
      AI327039 antibodyB cell ccl/lymphoma 1 antibodyB cell CLL/lymphoma 1 antibody
      B cell leukemia 1 antibodyB cell leukemia 1 antibodyB cell lymphoma 1 protein antibodyB-cell lymphoma 1 protein antibodyBCL 1 antibodyBCL-1 antibodyBCL-1 oncogene antibodyBCL1 antibodyBCL1 oncogene antibodyCCND 1 antibodyCCND1 antibodyCCND1 protein antibodyCCND1/FSTL3 fusion gene, included antibodyCCND1/IGHG1 fusion gene antibodyCCND1/IGHG1 fusion gene, included antibodyCCND1/IGLC1 fusion gene, included antibodyCCND1/PTH fusion gene, included antibodyCCND1_HUMAN antibodycD1 antibodyCyl 1 antibodyD11S287E antibodyG1/S specific cyclin D1 antibodyG1/S-specific cyclin-D1 antibodyParathyroid adenomatosis 1 antibodyPRAD1 antibodyPRAD1 oncogene antibodyU21B31 antibody
    see all

Anti-Cyclin D1 antibody [CD1.1] images

  • Immunohistochemical analysis of Huh7 tumour xenografts grown in mice treated with either control (left) or anti-Wnt1 antibody (right), staining Cyclin D1 with ab6152. Sections were fixed in acetone before incubation with primary antibody (1/250). Staining was detected using HRP.

References for Anti-Cyclin D1 antibody [CD1.1] (ab6152)

This product has been referenced in:
  • Wei W  et al. Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin. Mol Cancer 10:16 (2011). WB, IHC-P ; Human . Read more (PubMed: 21314951) »
  • Wei W  et al. Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. Mol Cancer 8:76 (2009). IHC-Fr ; Mouse . Read more (PubMed: 19778454) »

See all 11 Publications for this product

Product Wall

Displaying 1 - 10 of 15 results for Abreviews and Q&A

Application Western blot
Sample Human Cell lysate - whole cell (Human Fibroblast)
Loading amount 15 µg
Specification Human Fibroblast
Gel Running Conditions Reduced Denaturing (4-12% Bis-Tris Nupage gel)
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
Username

Verified customer

Submitted Feb 25 2013

Application Western blot
Sample Human Cell lysate - whole cell (glioblastoma cells)
Loading amount 50 µg
Specification glioblastoma cells
Gel Running Conditions Non-reduced Denaturing
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: RT°C
Username

Verified customer

Submitted Dec 04 2012

Application Immunohistochemistry (Frozen sections)
Sample Rat Tissue sections (Liver)
Specification Liver
Fixative Acetone
Permeabilization No
Blocking step Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 10% · Temperature: 21°C
Username

Verified customer

Submitted Nov 29 2012

Thank you for confirming this information and for your help and cooperation with this case.

As requested, I have asked our accounting department to issue you with a credit note. This can then be redeemed against the invoice of a future order. <...

Read More

Thank you for your message.

I am sorry to hear the suggestions have not improved the results on this occasion. I fully understand the concerns of the customerand it is disappointing the results have not been successful.

We are happy ...

Read More

Thank you for taking the time to complete our questionnaire and contact us. I am sorry to hear the customer has had difficulty obtaining satisfactory results from this antibody.

The details you have kindly provided will enable us to investigate...

Read More

Thank you for your reply.

All three of these antibodies were validated using a protocol similar to the following:

http://www.abcam.com/index.html?pageconfig=resource&rid=11389

These antibodies were tested using BSA as a bl...

Read More

Thank you for contacting us.
If we list an antibody as tested, that means the product has been validated for that application and we will cover it under our Abpromise guarantee. If we don't list an application as tested, it generally means that we do...

Read More

I have done some reading and for most mammalian antibodies will have a molar extinction coefficient equal to 210,000M-1cm-1. I hope this information helps and please let me know if there is anything else I can do to help.

Thanks for your call yesterday and for your patience while I have been in touch with the lab regarding ab6152. It looks like the antigen retrieval method recommended with this antibody is sodium citrate buffer instead of the standard citric acid bu...

Read More


Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"